Medical Cannabis Grown for Research

Bright Green Corp. Submits DEA Registration For Production of Schedule I, II Controlled Substances

The application follows the company’s approval from the New Mexico Board of Pharmacy this year.

Cannabis Reform Momentum Unprecedented in Recent Years

Nirit Bernstein to Speak at Cannabis Conference

FDA Issues Final Guidance for Clinical Research on Cannabis

More from Cannabis Business Times

Cannabis Industry Reacts to Biden’s Rescheduling Announcement

As Predicted, 4/20 Sales Surged During Cannabis Industry Holiday Weekend

DEA 2024 Report Focuses on THC Potency, Organized Crime, Youth Edible Consumption